Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, 712000, Shaanxi, China.
Key Laboratory of basic and new drug research of traditional Chinese medicine, Shaanxi University of Chinese Medicine, Xianyang, 712000, Shaanxi, China.
BMC Complement Med Ther. 2020 Nov 19;20(1):351. doi: 10.1186/s12906-020-03026-y.
This study aimed to identify the key genes and KEGG pathways in Carthamus tinctorius L. (Safflower) and Salvia miltiorrhiza Burge. (Salvia) for the treatment of cardio-cerebrovascular disease, and to explore their potential molecular mechanisms.
Compounds and targets in Safflower and Salvia were retrieved from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). We obtained targets of myocardial infarction (MI) and cerebral infarction (CI) data from Therapeutic Target Database (TTD), Drugbank and DisGeNET datasets. The network of Safflower, Salvia, CI and MI was established and then executing, and Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses of the functional characteristics were performed. The Chinese herbal prescription and target for CI and MI were obtained by searching in the database. Finally, the main pathways of Salvia and Safflower in Chinese patent medicines were analyzed. The MCAO model was established in rats, and compatibility of salvia with safflower was experimentally verified.
We obtained a total of 247 genes targeted by 52 compounds from Safflower and 119 genes targeted by 48 compounds from Salvia. In total, we identified 299 known therapeutic targets for the treatment of CI and 960 targets for the treatment MI. There are 23 common targets for Salvia, Safflower, MI, and CI. A total of 85 KEGG pathways were also enriched and intersected with the pathway of proprietary Chinese medicine to yield 25 main pathways. Safflower and Salvia have the best therapeutic effect in MCAO.
We identified gene lists for Safflower and Salvia in CI and MI. Bioinformatics and interaction analyses may provide new insight into the treatment of cardio-cerebrovascular diseases with Safflower and Salvia.
本研究旨在鉴定红花和丹参治疗心脑血管疾病的关键基因和 KEGG 途径，并探讨其潜在的分子机制。
从中药系统药理学数据库和分析平台（TCMSP）中检索红花和丹参中的化合物和靶点。从治疗靶点数据库（TTD）、Drugbank 和 DisGeNET 数据集获得心肌梗死（MI）和脑梗死（CI）的靶点数据。建立红花、丹参、CI 和 MI 的网络，然后进行京都基因与基因组百科全书（KEGG）和基因本体论（GO）分析，以研究其功能特征。通过在数据库中搜索，获得治疗 CI 和 MI 的中药方剂和靶点。最后，分析中药方剂中丹参和红花的主要途径。通过建立大鼠 MCAO 模型，实验验证了丹参与红花的配伍。
我们从红花中获得了 52 种化合物靶向的 247 个基因，从丹参中获得了 48 种化合物靶向的 119 个基因。总共鉴定出 299 个已知的治疗 CI 的治疗靶点和 960 个治疗 MI 的靶点。丹参、红花、MI 和 CI 共有 23 个共同靶点。共富集了 85 个 KEGG 途径，并与中药专利途径相交，得到 25 个主要途径。红花和丹参在 MCAO 中具有最佳的治疗效果。
我们鉴定了红花和丹参在 CI 和 MI 中的基因列表。生物信息学和相互作用分析可能为红花和丹参治疗心脑血管疾病提供新的思路。
